ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2408

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

Keith A. Sikora1, Joshua R. Bennett1, Zuoming Deng2, Wanxia Li Tsai3, April Brundidge3, Fatemeh Navid3, Gerlinde Layh-Schmitt3, Eric Hanson3, Massimo G. Gadina4, Louis M. Staudt5, Thomas A. Griffin6 and Robert A. Colbert3, 1Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5National Cancer Institute, National Institutes of Health, Bethesda, MD, 6Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: innate immunity, juvenile idiopathic arthritis (JIA), neutrophils, pediatric rheumatology and toll-like receptors

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Pediatric Rheumatology – Pathogenesis and Genetics - Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function mutations in MyD88 cause immunodeficiency, while somatic gain-of-function mutations have been linked to lymphoma. We investigated a child with a progressively destructive small-to-medium joint polyarticular JIA since the age of 2 with persistent neutrophil predominant synovial infiltrates.

Methods: We evaluated the patient and family members by whole exome sequencing (WES), peripheral blood immunophenotyping, and phosphorylated-STAT3 (p-STAT3) quantitation. Functional studies in monocytes and dermal fibroblasts included gene/protein expression, quantitation of neutrophil chemotaxis, and siRNA-mediated knockdown of MyD88 and NF-κB subunit p65 (p65). Wild type or S222R MyD88-GFP fusion proteins were re-expressed in MyD88-deficient THP-1 cells. NF-κB activity in THP-1 cells was measured via secreted embryonic alkaline phosphatase reporter assay.

Results:  WES revealed a de novo heterozygous missense mutation in MYD88(c.666T>G, p.Ser222Arg), which was confirmed by Sanger sequencing in both peripheral leukocytes and dermal fibroblasts. Immunophenotyping showed an absence of CD16+ monocytes, an expansion of CD4+ Th17 T cells, and the presence of a previously uncharacterized CD123+CD11c+ dendritic cell population, as well as markedly increased basal and stimulated p-STAT3 in monocytes and T and B lymphocytes in the patient. Peripheral monocytes exhibited a baseline interferon gene expression signature and increased expression of neutrophil and monocyte chemokines. Fibroblasts exhibited significantly greater baseline expression of CXCL chemokines compared to controls, which abated upon MyD88 or p65 knockdown. Re-expression of wild type or S222R MyD88-GFP fusion protein in MyD88-knockout THP-1 cells demonstrated increased NF-κB activation at baseline and with stimulation in S222R-MyD88-expressing cells.

Conclusion:  This is the first description of a de novo germline MyD88 mutation associated with severe polyarticular JIA. The gain-of-function effects demonstrated in the patient’s hematopoietic and non-hematopoietic cells offer a plausible mechanism for arthritis and support a role for single gene defects contributing to extreme JIA phenotypes.


Disclosure: K. A. Sikora, None; J. R. Bennett, None; Z. Deng, None; W. L. Tsai, None; A. Brundidge, None; F. Navid, None; G. Layh-Schmitt, None; E. Hanson, None; M. G. Gadina, None; L. M. Staudt, None; T. A. Griffin, None; R. A. Colbert, None.

To cite this abstract in AMA style:

Sikora KA, Bennett JR, Deng Z, Tsai WL, Brundidge A, Navid F, Layh-Schmitt G, Hanson E, Gadina MG, Staudt LM, Griffin TA, Colbert RA. Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/severe-juvenile-arthritis-associated-with-a-de-novo-gain-of-function-germline-mutation-in-myd88/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/severe-juvenile-arthritis-associated-with-a-de-novo-gain-of-function-germline-mutation-in-myd88/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology